Global Angina Pectoris Drugs Market 2017-2021

狭心症治療薬の世界市場2017-2021:β遮断薬、カルシウムチャネル遮断薬、硝酸薬、アンジオテンシン変換酵素阻害薬、その他

◆タイトル:Global Angina Pectoris Drugs Market 2017-2021
◆商品コード:IRTNTR14638
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年8月24日
◆ページ数:82
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:Healthcare and Life Sciences
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

Technavio社が発行した当調査レポートでは、狭心症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、狭心症治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は狭心症治療薬の世界市場が2017-2021年期間中に年平均4.05%成長すると予測しています。当レポート上に記載されている主な企業はAstraZeneca、Gilead、Novartis、Pfizer等です。

About Angina Pectoris Drugs
Angina is a type of chest pain or discomfort caused due to a coronary heart disease, specifically due to reduced blood flow to the heart. For angina pectoris drugs market, beta blockers remain the most preferred line of treatment. However, the treatment market witnesses a strong presence of other drug classes such as calcium channel blockers. Though the market is fragmented, large players such as AstraZeneca, Gilead, Novartis, and Pfizer hold significant positions.

Technavio’s analysts forecast the global angina pectoris drugs market to grow at a CAGR of 4.05% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global angina pectoris drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Angina Pectoris Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• Gilead
• Novartis
• Pfizer

[Other prominent vendors]
• ABayer HealthCare
• Bristol-Myers Squibb
• GlaxoSmithKline
• Merck
• Mylan
• Teva Pharmaceutical

[Market driver]
• Increase in chronic diseases
• For a full, detailed list, view our report

[Market challenge]
• Highly genericized market
• For a full, detailed list, view our report

[Market trend]
• Launch of novel pharmacologic agents
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by drug class
• Beta blockers
• Calcium channel blockers
• Nitrates
• Angiotensin-converting enzyme inhibitors
• Others

PART 08: Geographical segmentation
• Market overview based on geography
• Angina pectoris drugs market in Americas
• Angina pectoris drugs market in EMEA
• Angina pectoris market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Launch of novel pharmacologic agents
• Genomic medicines
• Growing strategic alliances

PART 12: Vendor landscape
• Competitive landscape

PART 13: Key vendor analysis
• AstraZeneca
• Gilead
• Novartis
• Pfizer
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Major angina types
Exhibit 02: Causes, symptoms, and risk factors for angina pectoris
Exhibit 03: Diagnosis and treatment of angina pectoris
Exhibit 04: Global angina pectoris drugs market snapshot
Exhibit 05: Global angina pectoris drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of the global angina pectoris drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules by key vendors 2016
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global angina pectoris market by drug class
Exhibit 11: Segmentation of global angina pectoris market by drug class 2016 and 2021
Exhibit 12: Global angina pectoris drugs market by beta blockers 2016-2021 ($ millions)
Exhibit 13: Common beta blockers used in cardiovascular disorders
Exhibit 14: Adverse effects of beta-blockers
Exhibit 15: Global angina pectoris drugs market by calcium channel blockers 2016-2021 ($ millions)
Exhibit 16: Common calcium channel blockers used for angina pectoris
Exhibit 17: Antianginal effects of calcium channel blockers
Exhibit 18: Adverse effects of calcium channel blockers
Exhibit 19: Nitrates for treatment of angina pectoris
Exhibit 20: Global angina pectoris drugs market by nitrates 2016-2021 ($ millions)
Exhibit 21: Effect of nitrates on cardiovascular system
Exhibit 22: Nitroglycerine used for the treatment and prevention of angina pectoris
Exhibit 23: Global angina pectoris drugs market by angiotensin-converting enzyme inhibitors 2016-2021 ($ millions)
Exhibit 24: Adverse effects of angiotensin-converting enzyme inhibitors
Exhibit 25: Other drug classes used for the treatment of angina pectoris
Exhibit 26: Global angina pectoris drugs market by others 2016-2021 ($ millions)
Exhibit 27: Antiplatelet agents used for treatment of angina pectoris
Exhibit 28: Anti-ischemic agent used in treatment of angina pectoris
Exhibit 29: Global angina pectoris drugs market share by geography 2016 and 2021
Exhibit 30: Global angina pectoris drugs market by geography 2016-2021 ($ millions)
Exhibit 31: Market scenario in Americas
Exhibit 32: Angina pectoris drugs market in Americas 2016-2021 ($ millions)
Exhibit 33: Market scenario in EMEA
Exhibit 34: Angina pectoris drugs market in EMEA 2016-2021 ($ millions)
Exhibit 35: Market scenario in APAC
Exhibit 36: Angina pectoris drugs market in APAC 2016-2021 ($ millions)
Exhibit 37: Top Asian countries in terms of population with diabetes
Exhibit 38: World population by age group: 2015-2050 (million)
Exhibit 39: Percentage of population aged 60 and above by region 2015-2050
Exhibit 40: Major complications of diabetes
Exhibit 41: Global obesity facts 2014
Exhibit 42: Competitive structure analysis of global angina pectoris drugs market
Exhibit 43: AstraZeneca: Key highlights
Exhibit 44: AstraZeneca: Strength assessment
Exhibit 45: AstraZeneca: Strategy assessment
Exhibit 46: AstraZeneca: Opportunity assessment
Exhibit 47: Gilead: Key highlights
Exhibit 48: Gilead: Strength assessment
Exhibit 49: Gilead: Strategy assessment
Exhibit 50: Gilead: Opportunity assessment
Exhibit 51: Novartis: Key highlights
Exhibit 52: Novartis: Strength assessment
Exhibit 53: Novartis: Strategy assessment
Exhibit 54: Novartis: Opportunity assessment
Exhibit 55: Pfizer: Key highlights
Exhibit 56: Pfizer: Strength assessment
Exhibit 57: Pfizer: Strategy assessment
Exhibit 58: Pfizer: Opportunity assessment



【掲載企業】

AstraZeneca, Gilead, Novartis, Pfizer, Bayer HealthCare, Bristol-Myers Squibb, GlaxoSmithKline, Merck , Mylan, and Teva Pharmaceutical.


★調査レポート[狭心症治療薬の世界市場2017-2021:β遮断薬、カルシウムチャネル遮断薬、硝酸薬、アンジオテンシン変換酵素阻害薬、その他] (Global Angina Pectoris Drugs Market 2017-2021 / IRTNTR14638)販売に関する免責事項
[狭心症治療薬の世界市場2017-2021:β遮断薬、カルシウムチャネル遮断薬、硝酸薬、アンジオテンシン変換酵素阻害薬、その他] (Global Angina Pectoris Drugs Market 2017-2021 / IRTNTR14638)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆